Boston Trust Walden Lets Go of 93,000 Qualys (QLYS) Shares
Summarize this article with:
By Cory Renauer – Apr 26, 2026 at 11:10AM ESTKey PointsSold 93,512 shares of Qualys; estimated transaction value $10.36 million (based on average Q1 2026 pricing)Quarter-end position value decreased by $57.95 million, reflecting both trading and share price movementChange equates to 0.085% of 13F reportable assets under managementPost-sale stake: 1,010,376 shares valued at $88.76 millionPosition now represents 0.73% of fund AUM, placing it outside the fund's top five holdingsWhat happenedAccording to a recent SEC filing dated April 24, 2026, Boston Trust Walden Corp sold 93,512 shares of Qualys (QLYS +0.36%) during the first quarter. The estimated transaction value is $10.36 million, based on the average unadjusted closing price for the quarter. The value of the fund’s stake in Qualys fell by $57.95 million quarter-over-quarter, a figure that includes both the effect of the sale and share price movements.What else to knowQualys now accounts for 0.73% of Boston Trust Walden Corp’s 13F reportable AUM following the reduction in sharesTop holdings after the filing:NASDAQ: GOOGL: $468.88 million (3.86% of AUM)NASDAQ: AAPL: $378.28 million (3.11% of AUM)NASDAQ: MSFT: $358.75 million (2.95% of AUM)NASDAQ: NVDA: $192.26 million (1.58% of AUM)NYSE: ATR: $170,062 million (1.4% of AUM)As of April 23, 2026, Qualys shares were priced at $84.04, down 31.0% over one year, trailing the S&P 500 by 63.2 percentage pointsCompany overviewMetricValuePrice (as of market close 2026-04-24)$84.34Market Capitalization$3.01 billionRevenue (TTM)$669.12 millionNet Income (TTM)$198.32 millionCompany snapshotQualys provides a suite of cloud-based IT, security, and compliance solutions, including vulnerability management, threat protection, endpoint detection, and web application security.The company operates a subscription-based business model, generating revenue through sales of its integrated cloud platform and related services to enterprise, government, and SMB clients.Its primary customers include organizations across industries such as financial services, healthcare, government, technology, and retail, with a focus on enterprises and public sector clients.Qualys, Inc. is a leading provider of cloud-based security and compliance solutions, serving a broad range of industries with scalable, integrated offerings. The company leverages its proprietary cloud platform to help organizations identify, assess, and remediate IT vulnerabilities efficiently. A consistent focus on automation and integration positions Qualys as a strategic partner for enterprises seeking robust cybersecurity and compliance management at scale.What this transaction means for investorsYou don’t have to look very far to find reasons why Boston Trust Walden might be disappointed with its Qualys investment. The cybersecurity stock is down more than 45% from the high-water mark it set last November.Boston Trust Walden doesn’t appear too concerned about Qualys losing customers to software that its customers can build themselves with increasingly useful generative artificial intelligence applications. It only sold off about 8% of its Qualys investment during the first quarter.Boston Trust Walden could have been encouraged by Qualys’ recent launch of AI agents. In March, the company launched the industry’s first AI agent for safe exploit validation and autonomous remediation. Qualys will report first-quarter results on May 5, 2026. In 2025, it reported sales that grew 10% to $669.1 million. Net income rose 14% last year to $222 million. Looking ahead, management expects total revenue to rise by 7% to 8% in 2026.Read NextApr 26, 2026 •By Cory RenauerCapricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 MillionApr 26, 2026 •By Lawrence Rothman, CFATSP Capital Triples Western Union Equity OwnershipApr 25, 2026 •By Seena HassounaGarrett Motion adds a turbocharged twist to Carmel's AI-heavy portfolioApr 25, 2026 •By Seena HassounaThe Fastly CEO Sold Shares. Here's What Actually Moves The StockApr 25, 2026 •By Cory RenauerCIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)Apr 25, 2026 •By Cory RenauerChicago Capital Slashes Its Alkami Technology Position by 1.6 Million SharesAbout the AuthorCory Renauer is a contributing Motley Fool healthcare analyst covering pharmaceuticals, biotechnology, and medical devices. Previously, Cory was a laboratory technician for the American Red Cross. He holds a bachelor’s degree in biology from Oakland University.TMFang4applesX@coryrenauerStocks MentionedQualysNASDAQ: QLYS$84.34(+0.36%)+$0.30*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.